Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec;59(1):1415-1424.
doi: 10.1080/13880209.2021.1990354.

Simultaneous measurement of tadehaginoside and its principal metabolite in rats by HPLC-MS/MS and its application in pharmacokinetics and tissue distribution study

Cai-Yun Zhang  1 , Ya-Ting Lu  2   3 , Yin-Feng Tan  1 , Qi-Bing Liu  1 , Lin Dong  1 , Ning Ma  4 , Wei-Ying Lu  4 , Zhi-Heng Su  2 , Xiao-Po Zhang  1
Affiliations

Simultaneous measurement of tadehaginoside and its principal metabolite in rats by HPLC-MS/MS and its application in pharmacokinetics and tissue distribution study

Cai-Yun Zhang et al. Pharm Biol. 2021 Dec.

Abstract

Context: Tadehaginoside, an active ingredient isolated from Tadehagi triquetrum (Linn.) Ohashi (Leguminosae), exhibited various biological activities. However, the pharmacokinetics and tissue distribution which affect tadehaginoside's therapeutic actions and application remain elusive.

Objective: To clarify the metabolism of tadehaginoside in vivo.

Materials and methods: The pharmacokinetics and tissue distribution of tadehaginoside and its metabolite p-hydroxycinnamic acid (HYD) were investigated using LC-MS/MS. Pharmacokinetic parameters were determined in 10 Sprague-Dawley rats divided into two groups, the intravenous group (5 mg/kg) and the oral group (25 mg/kg). For the tissue-distribution study, 20 rats were intravenously given tadehaginoside (5 mg/kg) before the experiment (n = 4). Biological samples were collected before drug administration (control group) and after drug administration.

Results: The linearity, accuracy, precision, stability, recovery and matrix effect of the method were well-validated and the results satisfied the requirements of biological sample measurement. Treatment with tadehaginoside via intragastric and intravenous administration, the calculated Cmax in rats was 6.01 ± 2.14 ng/mL and 109.77 ± 4.29 ng/mL, and Tmax was 0.025 ± 0.08 h and 0.08 h, respectively. The results indicated that the quick absorption of tadehaginoside was observed following intravenous administration, and tadehaginoside in plasma of rats with intragastric administration showed relatively low concentration may be due to the formation of its metabolite. Tissue-distribution study indicated that kidney and spleen were the major distribution organs for tadehaginoside in rats and there was no long-term accumulation in most tissues.

Discussion and conclusion: These results could provide clues for exploring the bioactivity of tadehaginoside based on its pharmacokinetic characteristics.

Keywords: metabolic profile; method development and validation; p-Hydroxycinnamic.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Figures

Figure 1.
Figure 1.
Structural formula of tadehaginoside (A), p-hydroxycinnamic acid (B) and quercetin (C).
Figure 2.
Figure 2.
Typical chromatograms of different samples (A1) Tadehaginoside in blank plasma; (A2) Tadehaginoside in blank matrix (spleen); (A3) Plasma sample at 5 min after intravenous administration of tadehaginoside; (A4) Kidney sample at 30 min after intravenous administration of tadehaginoside; (B1) Blank plasma spiked with IS; (B2) Blank matrix (spleen) spiked with IS; (B3) Plasma sample at 5 min after intravenous administration spiked with tadehaginoside and IS; (C1) HYD in Blank plasma; (C2) Plasma sample at 5 min after intravenous administration spiked with HYD; (C3) Plasma sample at 5 min after intragastric administration 5 min spiked with HYD.
Figure 3.
Figure 3.
Mean plasma concentration–time curves of tadehaginoside and p-hydroxycinnamic acid after (A), (C) intragastric administration (25 mg/kg); (B), (D) intravenous administration (5 mg/kg) to rats.
Figure 4.
Figure 4.
Concentration of tadehaginoside in rat tissues determined by HPLC-MS/MS.
Figure 5.
Figure 5.
The mass spectrum of tadehaginoside [(A), Q1-scan; (B) Full-scan], p-hydroxycinnamic acid [(C), Q1-scan; (D) Full-scan] and quercetin [(E), Q1-scan; (F) Full-scan].
See this image and copyright information in PMC

References

    1. Amalan V, Vijayakumar N, Indumathi D, Ramakrishnan A.. 2016. Antidiabetic and antihyperlipidemic activity of p-coumaric acid in diabetic rats, role of pancreatic GLUT 2: in vivo approach. Biomed Pharmacother. 84:230–236. - PubMed
    1. Aye MM, Aung HT, Sein MM, Armijos C.. 2019. A review on the phytochemistry, medicinal properties and pharmacological activities of 15 selected myanmar medicinal plants. Molecules. 24(2):293. - PMC - PubMed
    1. Azuma K, Ippoushi K, Nakayama M, Ito H, Higashio H, Terao J.. 2000. Absorption of chlorogenic acid and caffeic acid in rats after oral administration. J Agric Food Chem. 48(11):5496–5500. - PubMed
    1. Bhateria M, Ramakrishna R, Puttrevu SK, Yerrabelli S, Saxena AK, Bhatta RS.. 2016. Pre-clinical investigation of plasma pharmacokinetics and biodistribution of a novel antithrombotic agent S002-333 in mice using LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 1031:154–162. - PubMed
    1. Chamberlain CA, Rubio VY, Garrett TJ.. 2019. Impact of matrix effects and ionization efficiency in non-quantitative untargeted metabolomics. Metabolomics. 15(10):1–9. - PubMed

Publication types

LinkOut - more resources